Kodiak Sciences Inc. (KOD)
NASDAQ: KOD · Real-Time Price · USD
28.81
-1.08 (-3.61%)
At close: Dec 29, 2025, 4:00 PM EST
30.06
+1.25 (4.34%)
After-hours: Dec 29, 2025, 6:42 PM EST
Kodiak Sciences Employees
Kodiak Sciences had 109 employees as of December 31, 2024. The number of employees decreased by 2 or -1.80% compared to the previous year.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$1,993,908
Market Cap
1.52B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 109 | -2 | -1.80% |
| Dec 31, 2023 | 111 | -1 | -0.89% |
| Dec 31, 2022 | 112 | 19 | 20.43% |
| Dec 31, 2021 | 93 | 21 | 29.17% |
| Dec 31, 2020 | 72 | 33 | 84.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KOD News
- 10 days ago - Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 12 days ago - Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock - PRNewsWire
- 14 days ago - Kodiak Sciences Announces Proposed Public Offering of Common Stock - PRNewsWire
- 6 weeks ago - Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results - PRNewsWire
- 6 weeks ago - Kodiak Sciences to Present at Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) - PRNewsWire
- 3 months ago - New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) - PRNewsWire
- 4 months ago - Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI) - PRNewsWire